Finerenone

Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist, a class of drug that blocks the receptor for the hormone aldosterone ^[1]. It was developed by Bayer and marketed as Kerendia, receiving approval in the United States in 2021 and in the European Union the following year ^[1]. It is taken as an oral tablet and is indicated to lower the risk of kidney function decline, kidney failure, cardiovascular death, heart attack and hospitalization for heart failure in adults with chronic kidney disease linked to type 2 diabetes ^[1][2].

Unlike the older steroidal mineralocorticoid receptor antagonists spironolactone and eplerenone, finerenone has a different chemical structure and binds more selectively to the mineralocorticoid receptor, with little activity at other steroid hormone receptors ^[1]. This selectivity is intended to reduce hormonal side effects, such as the breast tenderness seen with spironolactone, while still countering the receptor's role in promoting inflammation and tissue scarring ^[1].

Its benefits were established in two large phase III trials. FIDELIO-DKD, which enrolled patients with more advanced kidney disease, found that finerenone lowered the combined risk of kidney disease progression and death from renal causes, and also reduced cardiovascular events, compared with placebo ^[1]. FIGARO-DKD, which included patients across a wider range of kidney disease, showed a reduction in cardiovascular events driven largely by fewer hospitalizations for heart failure ^[2]. A prespecified pooled analysis of both trials, called FIDELITY, confirmed consistent cardiovascular and kidney benefits across the spectrum of disease ^[3].

Finerenone is a prescription-only medicine given on top of standard therapy that blocks the renin-angiotensin system ^[1]. Its most important side effect is hyperkalemia, a rise in blood potassium that requires monitoring; low blood pressure and low blood sodium have also been reported ^[1].

Finerenone is a prescription medicine whose main risk is hyperkalemia, or high blood potassium, so potassium and kidney function are checked before starting and during treatment. Other effects include low blood pressure and low sodium. It should not be combined with other potassium sparing agents or with strong CYP3A4 inhibitors such as certain azole antifungals, which sharply raise its levels, and it is avoided in adrenal insufficiency.

Finerenone is a nonsteroidal mineralocorticoid receptor antagonist cleared almost entirely by CYP3A4, which makes that pathway the dominant interaction. Strong CYP3A4 inhibitors such as itraconazole, ketoconazole, clarithromycin, ritonavir and nefazodone raise finerenone exposure several-fold and are treated as contraindicated; grapefruit juice acts by the same intestinal mechanism. Strong and moderate CYP3A4 inducers, including rifampin, carbamazepine, phenytoin, phenobarbital and St John's wort, cut exposure enough that the kidney and cardiovascular benefit is lost.

The pharmacodynamic interaction is hyperkalemia. Finerenone reduces potassium excretion, so combining it with potassium supplements, potassium-sparing diuretics, other mineralocorticoid antagonists such as spironolactone or eplerenone, ACE inhibitors, ARBs or trimethoprim adds to that effect. Serious hyperkalemia is the single most common reason finerenone is discontinued, and reduced renal function magnifies every one of these interactions.

Checking a whole stack? Run it through interactions + stacks.

Finerenone was developed by the German pharmaceutical company Bayer as a nonsteroidal, selective mineralocorticoid receptor antagonist, designed through medicinal chemistry to improve on the older steroidal agents spironolactone and eplerenone. Its development aimed specifically at the inflammation and fibrosis driven by mineralocorticoid receptor overactivation in the kidney and heart, rather than blood pressure alone.

Two landmark phase III trials anchored its evidence base; FIDELIO-DKD, reported in 2020, showed it slowed the progression of diabetic kidney disease, and FIGARO-DKD, reported in 2021, demonstrated cardiovascular benefits including reduced heart failure risk. On the strength of this program, the Food and Drug Administration approved finerenone in 2021 under the brand name Kerendia, making it the first drug of its kind for chronic kidney disease associated with type 2 diabetes. A pooled analysis, FIDELITY, later combined data from more than thirteen thousand patients across both trials.

Finerenone has quickly earned a strong reputation as a genuinely novel tool for protecting the kidneys and heart in people with diabetic kidney disease, an area where treatment options had long been limited. Nephrologists and cardiologists appreciate that it targets the inflammation and scarring underlying organ damage, with benefits that appear largely independent of its modest effect on blood pressure.

Its nonsteroidal, highly selective design is a real advance; by sparing the androgen, progesterone, and estrogen receptors, it sidesteps much of the hormonal side-effect burden that limited spironolactone. Backed by two large positive outcome trials, it fills a distinct niche alongside SGLT2 inhibitors and renin-angiotensin blockers in modern kidney care. As with all agents in its class, it requires monitoring of potassium levels, a manageable consideration weighed against its documented organ-protective benefits.